A Mild and Versatile Method for the Preparation of Oximes by Use of Calcium Oxide

A convenient method for the cleavage of aldehydes and ketones to their corresponding oximes with CaO is described.

A convenient and eco-friendly cerium(III) chloride-catalysed synthesis of methoxime derivatives of aromatic aldehydes and ketones

The use of CeCl₃·7H₂O as an efficient and eco-friendly promoter for the convenient synthesis of methoximes derived from aromatic aldehydes and ketones, is reported. The transformations entail the use of equimolar amounts of MeONH₂·HCl and NaOAc in EtOH at 50°C, and no special precautions are needed with regard to the presence of oxygen. The scope and limitations of the transformation were studied and a reaction mechanism was proposed.

Review of the synthesis of acyclic and cyclic oxime ethers

Oxime ethers have attracted much attention due to their potential biological activities and wide variety of synthetic applications.

New and improved methods for the conversion of nitroalkanes into geminal chloronitroso compounds

The scope and limitations of a new method for the preparation of geminal chloronitroso compounds involving treatment of a nitronate anion with oxalyl chloride are described in full, and a milder, high yielding, and more chemoselective variant using the derived silyl nitronate is presented.

Synthesis of Polyfunctionalized 4H-Pyrans

Amberlyst A21 catalyzed one-pot three-component coupling of aldehyde and malononitrile with active methylene compounds such as acetylacetone and ethyl acetoacetate for the synthesis of pharmaceutically important polyfunctionalized 4H-pyrans has been reported. Simple experimental procedure, no chromatographic purification, no hazardous organic solvents, easy recovery and reusability of the catalyst, and room temperature reaction conditions are some of the highlights of this protocol for the synthesis of pharmaceutically relevant focused libraries.

Thalidomide analogues demonstrate dual inhibition of both angiogenesis and prostate cancer

The identification of agents with antiproliferative activity against endothelial cells has significant value for the treatment of many angiogenesis-dependent pathologies. Herein, we describe the discovery of a series of thalidomide analogues possessing inhibitory effects against both endothelial and prostate cancer cells. More specifically, several analogues exhibited low micromolar to mid-nanomolar potency in the inhibition of human microvascular endothelial cell (HMEC) proliferation, both in the presence and absence of vascular endothelial growth factor (VEGF), with the tetrafluorophthalimido class of compounds demonstrating the greatest potency. Additionally, all the compounds were screened against two different androgen independent prostate cancer cell lines (PC-3 and DU-145). Again, the tetrafluorophthalimido analogues exhibited the greatest effect with GI(50) values in the low micromolar range. Thalidomide was found to demonstrate selective inhibition of androgen receptor positive LNCaP prostate cancer cells. Furthermore, we showed that, as an example, tetrafluorophthalimido analogue 19 was able to completely inhibit the prostate specific antigen (PSA) secretion by the LNCaP cell line, while thalidomide demonstrated a 70% inhibition. We have also demonstrated that a correlation exists between HMEC and prostate cancer cell proliferation for this structural class. Altogether, our study suggests that these analogues may serve as promising leads for the development of agents that target both androgen dependent and independent prostate cancer and blood vessel growth.